Categories Earnings, Health Care

Earnings Summary: Quest Diagnostics (DGX) reaffirms FY25 guidance

Quest Diagnostics Incorporated (NYSE: DGX), a provider of diagnostic information services, has reaffirmed its outlook for fiscal 2025 and provided cautious first-quarter guidance.

  • Quest said it continues to expect full-year 2025 net revenue to be in the range of $10.70 billion to $10.85 billion
  • The guidance represents an 8.4% to $9.9% increase in full-year net revenue
  • The company reaffirmed its earnings per share guidance for FY25, on a reported basis, in the $8.34-$8.59 range
  • Adjusted earnings per share are expected to be between $9.55 and $9.80 in the fiscal year, which is in line with the previous guidance
  • The management continues to expect cash provided by operations to be approximately $1.45 billion in FY25, and capital expenditure to be $500 million
  • For the first quarter of 2025, the company expects the worse-than-anticipated weather to create a headwind to revenue of around $25 million, and to EPS of about $0.10

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

Infographic: How Constellation Brands (STZ) performed in Q3 2026

Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to

BLK Q4 Preview: BlackRock appears poised for another earnings beat

BlackRock, Inc. (NYSE: BLK), the largest asset management company, is set to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s

A look at Best Buy’s (BBY) progress on its growth strategy

Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top